EDE meets 2 Korean CGT firms as UAE weighs cell and gene therapy access

Emirates Drug Establishment (EDE) Director General Dr. Fatima Al Kaabi visited Biosolution and Helixmith in Seoul on 8 September 2026 to discuss regulatory cooperation and potential UAE entry routes for Korean cell and gene therapies.

The story matters first to Dubai hospital COOs, pharmacy heads and CFOs. Cell and gene therapies (CGTs) require licensed handling, specialist prescribing, adverse-event protocols and reimbursement approval before the first patient is scheduled. In Dubai, facility operations sit with the Dubai Health Authority (DHA). In Abu Dhabi and Al Ain, they sit with the Department of Health - Abu Dhabi (DOH). In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, provider licensing links back to the Ministry of Health and Prevention (MOHAP), while EDE controls medical product regulation at federal level.

What EDE saw in Seoul

Korea Biomedical Review reported on 9 September 2026 that EDE officials toured the Biosolution and Helixmith R&D centre in Magok, western Seoul. The visit was supported by South Korea's Ministry of Food and Drug Safety (MFDS) and the Korea Biomedicine Industry Association (KoBIA).

The delegation included Shamsa Atiq Al Muhairi, advisor to the chair of EDE's IMC, according to the Korea Biomedical Review photo caption. Korean attendees included Ahn Young-jin, director general of the MFDS Biopharmaceuticals and Herbal Medicine Bureau, Lim Sang-woo, director of the MFDS Biopharmaceutical Quality Management Division, and Lee Jung-sun, CEO of Biosolution.

Biosolution presented MCTT HCE, a three-dimensional corneal epithelial model, and KeraSkin, a three-dimensional human skin model used in alternatives to animal testing. Helixmith and Biosolution also briefed the UAE delegation on VM202, also known as Engensis, a plasmid DNA-based gene therapy. A VM202 version licensed to Beijing Northland Biotech received marketing authorization in China for critical limb ischemia in May 2026, according to Korea Biomedical Review.

Why UAE operators should care

EDE says it was established on 29 September 2023 and is the only federal authority responsible for regulating medical and pharmaceutical products, including medical devices, blood derivatives, genetically modified organisms and stem cells. That mandate puts CGT market access in a different category from ordinary specialty-drug procurement.

For Dubai providers, the practical question is whether a CGT product, once federally authorized, can be delivered inside an existing oncology, hematology, vascular or pharmacy service line. DHA licensing, pharmacy storage rules, informed consent, infection control, lab interfaces and emergency escalation pathways would all need review before launch. Abu Dhabi providers face the same operational question under DOH, with payer discussions likely to involve Daman and Thiqa where the patient population and policy terms apply. For privately insured patients, Sukoon and other UAE insurers will need case-by-case benefit decisions unless a product has explicit policy coverage.

• Ask vendors for the EDE authorization status, MFDS approval status and any reference-authority pathway being used.
• Request the full episode price, not only the medicine price.
• Check whether apheresis, ICU monitoring, genetic testing and follow-up are billed separately.
• Document eligibility criteria before marketing to patients.

International CAR-T drug acquisition prices commonly sit around $373,000 to $475,000, or about AED 1.37 million to AED 1.74 million, before hospital admission, lymphodepletion, laboratory work, toxicity management and follow-up. UAE operators should treat that range as a budgeting reference, not a UAE tariff. The actionable number is the written quote from the manufacturer, distributor, treating facility and insurer for one defined indication.

What comes next in the UAE

The near-term signal is regulatory, not commercial. Korea Biomedical Review said Korean companies asked EDE officials about authorization, review procedures and requirements for UAE market entry. Operators should watch for EDE guidance, named product submissions, and any public EDE-MFDS pathway that shortens review for Korean-approved therapies.

Patients will see value only if access rules are clear. Clinics should avoid advertising named CGT treatments until EDE authorization, facility readiness and payer position are confirmed. Insurers should prepare prior-authorization templates that ask for diagnosis, line of therapy, biomarker or genetic evidence, treating centre credentials and post-treatment monitoring plan.

Pharmacy leaders tracking licensed dispensing and provider partners can use the UAE Open Healthcare Directory to identify licensed pharmacy providers before building referral, sourcing or patient-support workflows.